Company intelligence / Profile preview

Montreal EpiTerapia

Montreal, Quebec, Canada

Ownership: Private
Development stage: Other

Overview

Montreal EpiTerapia is a Canadian biotechnology company focused on the development of epigenetic-based therapies for the treatment of cancer. The company's research centers on targeting DNA methylation pathways, specifically focusing on DNA methyltransferase 1 (DNMT1) and Methyl-CpG-binding domain protein 2 (MBD2) to reverse gene silencing in tumor cells. By developing small molecule inhibitors that modulate these epigenetic markers, Montreal EpiTerapia aims to restore the expression of tumor suppressor genes and enhance the efficacy of existing cancer treatments. The company is currently in the pre-clinical stage, advancing its lead candidates through early-stage validation and optimization.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Montreal EpiTerapia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Montreal EpiTerapia.

Explore the full profile